» Articles » PMID: 15890952

Differences in the Fitness of Two Diverse Wild-type Human Immunodeficiency Virus Type 1 Isolates Are Related to the Efficiency of Cell Binding and Entry

Overview
Journal J Virol
Date 2005 May 14
PMID 15890952
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of one primary human immunodeficiency virus type 1 (HIV-1) isolate to outcompete another in primary CD4+ human lymphoid cells appears to be mediated by the efficiency of host cell entry. This study was designed to test the role of entry on fitness of wild-type HIV-1 isolates (e.g., replicative capacity) and to examine the mechanism(s) involved in differential entry efficiency. The gp120 coding regions of two diverse HIV-1 isolates (the more-fit subtype B strain, B5-91US056, and less-fit C strain, C5-97ZA003) were cloned into a neutral HIV-1 backbone by using a recently described yeast cloning technique. The fitness of the primary B5 HIV-1 isolates and its env gene cloned into the NL4-3 laboratory strain had similar fitness, and both were more fit than the C5 primary isolate and its env/NL4-3 chimeric counterpart. Increased fitness of the B5 over C5 virus was mediated by the gp120 coding region of the env gene. An increase in binding/fusion, as well as decreased sensitivity to entry inhibitors (PSC-RANTES and T-20), was observed in cell fusion assays mediated by B5 gp120 compared to C5 gp120. Competitive binding assays using a novel whole virus-cell system indicate that the primary or chimeric B5 had a higher avidity for CD4/CCR5 on host cells than the C5 counterpart. This increased avidity of an HIV-1 isolate for its cell receptors may be a significant factor influencing overall replicative capacity or fitness.

Citing Articles

In vitro replicative potential of an HIV-1/MO intergroup recombinant virus compared to HIV-1/M and HIV-1/O parental viruses.

Moisan A, Tombette F, Vautrin M, Alessandri-Gradt E, Mourez T, Plantier J Sci Rep. 2024; 14(1):1730.

PMID: 38242913 PMC: 10799055. DOI: 10.1038/s41598-024-51873-3.


Consequences of HIV infection in the bone marrow niche.

Herd C, Mellet J, Mashingaidze T, Durandt C, Pepper M Front Immunol. 2023; 14:1163012.

PMID: 37497228 PMC: 10366613. DOI: 10.3389/fimmu.2023.1163012.


Net charge and position 22 of the V3 loop are associated with HIV-1 tropism in recently infected female sex workers in Nairobi, Kenya.

Abisi H, Otieno L, Irungu E, Onyambu F, Chepchirchir A, Anzala O Medicine (Baltimore). 2023; 101(49):e32024.

PMID: 36626483 PMC: 9750520. DOI: 10.1097/MD.0000000000032024.


Pervasive and non-random recombination in near full-length HIV genomes from Uganda.

Grant H, Hodcroft E, Ssemwanga D, Kitayimbwa J, Yebra G, Esquivel Gomez L Virus Evol. 2020; 6(1):veaa004.

PMID: 32395255 PMC: 7204518. DOI: 10.1093/ve/veaa004.


Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.

Umviligihozo G, Cobarrubias K, Chandrarathna S, Jin S, Reddy N, Byakwaga H J Virol. 2020; 94(14).

PMID: 32376625 PMC: 7343213. DOI: 10.1128/JVI.00293-20.


References
1.
Barbour J, Wrin T, Grant R, Martin J, Segal M, Petropoulos C . Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002; 76(21):11104-12. PMC: 136622. DOI: 10.1128/jvi.76.21.11104-11112.2002. View

2.
Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G . CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol. 1998; 72(6):4694-703. PMC: 109994. DOI: 10.1128/JVI.72.6.4694-4703.1998. View

3.
Ball S, Abraha A, Collins K, Marozsan A, Baird H, Quinones-Mateu M . Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol. 2002; 77(2):1021-38. PMC: 140829. DOI: 10.1128/jvi.77.2.1021-1038.2003. View

4.
Labrosse B, Labernardiere J, Dam E, Trouplin V, Skrabal K, Clavel F . Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol. 2002; 77(2):1610-3. PMC: 140831. DOI: 10.1128/jvi.77.2.1610-1613.2003. View

5.
Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View